1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

 
• By Alaric DeArment

Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.

• Source: Shutterstock

Fresh off its approval in the fourth quarter of 2023 for the treatment of obese and overweight adults, Eli Lilly and Company’s Zepbound (tirzepatide) looks likely to win approval in a related disease area, moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, thanks to positive topline Phase III results.

The Indianapolis-based drug maker reported on 17 April results from two SURMOUNT-OSA trials showing that tirzepatide, administered at 10mg or 15mg, significantly reduced the apnea-hypopnea index (AHI) compared with placebo, the primary endpoint for the two studies, which respectively tested the drug in patients not on continuous positive airway pressure (CPAP) therapy and patients who were on CPAP

Key Takeaways

  • Eli Lilly reported positive topline results from two Phase III trials of tirzepatide in moderate-to-severe obstructive sleep apnea among adults with obesity.

  • The results of both trials showed greater than 50% reductions in the apnea-hypopnea index, both for patients using CPAP machines and those not using them

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.